Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Specialised Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Treeway Licensing Deal with Specialised Therapeutics
Details : Under the licensing agreement, ST will be responsible for all marketing, regulatory and distribution activities of TW001, a unique oral formulation of edaravone which works by reducing the oxidative damage associated with neuron death in ALS, in Australi...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 28, 2023
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Specialised Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
ASURE: Alzheimer Study Using oRal Edaravone
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 12, 2022
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Study Phase : Phase III
Recipient : Ferrer Internacional
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Ferrer Signs License Agreement To Develop An Oral Formulation Treatment For Patients With ALS
Details : FNP122 is an oral formulation of edaravone, a compound that prevents oxidative stress on a cellular level. Therefore, reducing oxidative stress can delay the progression of ALS.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 20, 2021
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : Ferrer Internacional
Deal Size : Undisclosed
Deal Type : Licensing Agreement